DOI QR코드

DOI QR Code

Association of Adiponectin Receptor (Adipo-R1/-R2) Expression and Colorectal Cancer

  • Ayyildiz, Talat ;
  • Dolar, Enver ;
  • Ugras, Nesrin ;
  • Adim, Saduman Balaban ;
  • Yerci, Omer
  • Published : 2014.11.28

Abstract

Introduction: Human adiponectin (ApN) is a 30 kDa glycoprotein of 244-amino acids which is extensively produced by adipocytes. ApN acts via two receptors, namely adiponectin receptor-1 (Adipo-R1) and adiponectin receptor-2 (Adipo-R2). Studies have shown the presence of Adipo-R1 and Adipo-R2 expression immunohistochemically in human colorectal cancers (CRCs). However, only a few studies exist which investigated effects of adiponectin receptor expression on CRC characteristics. Objectives: In the present study, we aimed to explore Adipo-R1/-R2 expression in human colorectal cancers and any association with clinicopathological characteristics and survival. Materials and Methods: The study enrolled 58 colorectal cancer patients with tumor resection and a control group of 30 subjects with normal colon mucosa. Results: Positivity for Adipo-R1/-R2 expression was significantly more common in the control group in comparison to the patient group (both p<0.001). There was no significant association between Adipo-R1/-R2 expression and clinicopathological characteristics including age, sex tumor location, pTNM stage, Duke's stage, metastasis, histological differentiation, perineural invasion, venous invasion sex, lymphatic invasion, cancer-related mortality, tumor size and recurrence. Adipo- R1/-R2 positivity was also not significantly linked to progression-free or overall survival [p values (0.871, 0.758) and (0.274, 0.232), respectively]. Conclusions: Although significantly reduced Adipo-R1/-R2 expression was found in colorectal cancer patients, it had no influence on survival.

Keywords

Adiponectin receptor;Adipo-R1/-R2;colorectal carcinoma;prognosis

References

  1. Ayyildiz T, Dolar E, Ugras N, et al (2014). Lack of any prognostic relationship between adiponectin receptor (Adipo R1/R2) expression for early/advanced stage gastric cancer. Asian Pac J Cancer Prev, 15, 4711-16. https://doi.org/10.7314/APJCP.2014.15.11.4711
  2. Barresi V, Tuccari G, Barresi G (2009a). Adiponectin immunohistochemical expression in colorectal cancer and its correlation with histological grade and tumour microvessel density. Pathology, 41, 533-8. https://doi.org/10.1080/00313020903071553
  3. Barresi V, Grosso M, Giuffre G, Tuccari G, Barresi G (2009b). The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clin Pathol, 62, 705-9. https://doi.org/10.1136/jcp.2009.066175
  4. Brakenhielm E, Veitonmaki N, Cao R, et al (2004). Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA, 101, 2476-81 https://doi.org/10.1073/pnas.0308671100
  5. Byeon JS, Jeong JY, Kim MJ, et al (2010). Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer, 127, 2758-67. https://doi.org/10.1002/ijc.25301
  6. Chen MW, Ye S, Zhao LL, et al (2012). Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol, 29, 3129-35. https://doi.org/10.1007/s12032-012-0280-2
  7. Cnop M, Havel PJ, Utzschneider KM, et al (2003). Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 46, 459-69.
  8. Colussi D, Brandi G, Bazzoli F, Ricciardiello L (2013). Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci, 14, 16365-85. https://doi.org/10.3390/ijms140816365
  9. Dal Maso L, Augustin LS, Karalis A, et al (2004). Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab, 89, 1160-3. https://doi.org/10.1210/jc.2003-031716
  10. Dalamaga M, Diakopoulos KN, Mantzoros CS (2012). The role of adiponectin in cancer: a review of current evidence. Endocr Rev, 33, 547-94. https://doi.org/10.1210/er.2011-1015
  11. Dancey JE (2002). Clinical development of mammalian target of rapamycin inhibitors. Hematol Oncol Clin North Am, 16, 1101-14 . https://doi.org/10.1016/S0889-8588(02)00051-5
  12. Fukumoto J, Otake T, Tajima O, et al (2008). Adiponectin and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci, 99, 781-6. https://doi.org/10.1111/j.1349-7006.2008.00745.x
  13. Goldfine AB, Kahn CR (2003). Adiponectin: linking the fat cell to insulin sensitivity. Lancet, 362, 1431-2. https://doi.org/10.1016/S0140-6736(03)14727-7
  14. Gonullu G, Kahraman H, Bedir A, et al (2010). Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis, 25, 205-12. https://doi.org/10.1007/s00384-009-0828-6
  15. Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev, 13, 395-8. https://doi.org/10.7314/APJCP.2012.13.1.395
  16. Ho GY, Wang T, Gunter MJ, et al (2012). Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res, 72, 3029-37. https://doi.org/10.1158/0008-5472.CAN-11-2771
  17. Huang S, Houghton PJ (2003). Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol, 3, 371-77. https://doi.org/10.1016/S1471-4892(03)00071-7
  18. Ishikawa M, Kitayama J, Kazama S, et al (2005). Plasma adiponectin and gastric cancer. Clin Cancer Res, 11, 466-72.
  19. Joshi RK, Lee SA (2014). Obesity related adipokines and colorectal cancer: a review and meta-analysis. Asian Pac J Cancer Prev, 15, 397-405. https://doi.org/10.7314/APJCP.2014.15.1.397
  20. Kadowaki T, Yamauchi T, Kubota N, et al (2006). Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 116, 1784-92. https://doi.org/10.1172/JCI29126
  21. Kamada Y, Matsumoto H, Tamura S, et al (2007). Hypoadiponectinemia accelerates hepatic tumor formation in nonalcoholic steatohepatitis mouse model. J Hepatol, 47, 556-64. https://doi.org/10.1016/j.jhep.2007.03.020
  22. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G (2002). Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care, 25, 971- 6. https://doi.org/10.2337/diacare.25.6.971
  23. Kelesidis I, Kelesidis T, Mantzoros CS (2006). Adiponectin and cancer: a systematic review. Br J Cancer. 94, 1221-5. https://doi.org/10.1038/sj.bjc.6603051
  24. Kojima S, Kojima S, Maruyoshi H, et al (2011). Hypercholesterolemia and hypoadiponectinemia are associated with necrotic core-rich coronary plaque. Int J Cardiol, 147, 371-6. https://doi.org/10.1016/j.ijcard.2009.09.536
  25. Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E (2009). Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis, 24, 275-81. https://doi.org/10.1007/s00384-008-0605-y
  26. Lukanova A, Soderberg S, Kaaks R, Jellum E, Stattin P (2006). Serum adiponectin is not associated with risk of CRC. Cancer Epidemiol Biomarkers Prev, 15, 401-2. https://doi.org/10.1158/1055-9965.EPI-05-0836
  27. Mantzoros C, Petridou E, Dessypris N, et al (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab, 89,1102-7. https://doi.org/10.1210/jc.2003-031804
  28. Matsuzawa Y, Shimomura I, Kihara S, et al (2003). Importance of adipocytokines in obesity-related diseases. Horm Res, 3, 56-9.
  29. Michalakis K, Williams CJ, Mitsiades N, et al (2007). Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev, 16, 308-13. https://doi.org/10.1158/1055-9965.EPI-06-0621
  30. Moore LL, Bradlee ML, Singer MR, et al (2004). BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int J Obes Relat Metab Disord, 28, 559-67. https://doi.org/10.1038/sj.ijo.0802606
  31. Murphy TK, Calle EE, Rodriguez C et al (2000). Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol, 152, 847-54. https://doi.org/10.1093/aje/152.9.847
  32. Oldham S, Hafen E (2003). Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control. Trends Cell Biol, 13, 79-85. https://doi.org/10.1016/S0962-8924(02)00042-9
  33. Otake S, Takeda H, Suzuki Y, et al (2005). Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res, 11, 3642-6. https://doi.org/10.1158/1078-0432.CCR-04-1868
  34. Ouchi N, Kihara S, Arita Y, et al (1999). Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation, 100, 2473-6. https://doi.org/10.1161/01.CIR.100.25.2473
  35. Ouchi N, Kihara S, Arita Y, et al (2001). Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation, 103, 1057-63. https://doi.org/10.1161/01.CIR.103.8.1057
  36. Philp AJ, Campbell IG, Leet C, et al (2001). The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res, 61, 7426-29.
  37. Rodrigues VS, Milanski M, Fagundes JJ, et al (2012). Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease. Clin Exp Immuno, 170, 358-64. https://doi.org/10.1111/j.1365-2249.2012.04660.x
  38. Saxena A, Baliga MS, Ponemone V, et al (2013). Mucus and adiponectin deficiency: role in chronic inflammation-induced colon cancer. Int J Colorectal Dis, 28,1267-79 https://doi.org/10.1007/s00384-013-1664-2
  39. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin , 62:220-41. https://doi.org/10.3322/caac.21149
  40. Vogt PK (2001). PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med, 7, 482-4. https://doi.org/10.1016/S1471-4914(01)02161-X
  41. Wei EK, Giovannucci E, Fuchs CS, Willet WC, Mantzoros CS (2005). Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst, 97, 1688-94. https://doi.org/10.1093/jnci/dji376
  42. Williams CJ, Mitsiades N, Sozopoulos E, et al (2008). Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer, 15, 289-99. https://doi.org/10.1677/ERC-07-0197
  43. Wolpin BM, Mayer RJ (2008). Systemic treatment of colorectal cancer. Gastroenterol, 134, 1296-10. https://doi.org/10.1053/j.gastro.2008.02.098
  44. Yamauchi T, Kamon J, Ito Y, et al (2003). Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 423, 762-9. https://doi.org/10.1038/nature01705
  45. Yang WS, Lee WJ, Funahashi T, et al (2002). Plasma adiponectin levels in overweight and obese Asians. Obes Res, 10, 1104-10. https://doi.org/10.1038/oby.2002.150
  46. Yoneda K, Tomimoto A, Endo H, et al (2008). Expression of adiponectin receptors, Adipo-R1 and Adipo-R2, in normal colon epithelium and colon cancer tissue. Oncol Rep, 20, 479-83.

Cited by

  1. Adipo-R1 and Adipo-R2 Expression in Colorectal Adenomas and Carcinomas vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.367
  2. Associations of Serum Isoflavone, Adiponectin and Insulin Levels with Risk for Epithelial Ovarian Cancer: Results of a Case-control Study vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4987
  3. Adiponectin and colorectal cancer vol.47, pp.2, 2017, https://doi.org/10.1007/s00595-016-1334-4
  4. Bone Marrow Adipocyte: An Intimate Partner With Tumor Cells in Bone Metastasis vol.9, pp.1664-2392, 2018, https://doi.org/10.3389/fendo.2018.00339
  5. Adiponectin as Link Factor between Adipose Tissue and Cancer vol.20, pp.4, 2019, https://doi.org/10.3390/ijms20040839